Treatment of depression improves glycated hemoglobin in patients with type 2 diabetes mellitus. Experience in general practice [Il trattamento della depressione migliora l’emoglobina glicata nel diabete mellito di tipo 2: Un'esperienza in medicina generale]
Passamonti M.,Societa Italiana di Medicina Generale e delle Cure Primarie SIMG |
Musazzi L.,Polo Didattico |
Pigni M.,Societa Italiana di Medicina Generale e delle Cure Primarie SIMG |
Testolin E.,Societa Italiana di Medicina Generale e delle Cure Primarie SIMG |
And 3 more authors.
Giornale Italiano di Diabetologia e Metabolismo | Year: 2015
Comorbid diabetes and depression pose a major clinical chal- lenge as each condition worsens the outcome of the other. The relationship between type 2 diabetes (T2DM) and depression is amply documented. We designed a retrospective study in our practice to assess the changes in glycated hemoglobin (HbA1c) in patients with T2DM concomitant with depression, before and after treatment with an anti-depressant drug that achieved remission of the depressive symptoms. In all, 32 patients met the inclusion criteria (M/F 8/24; mean age ± SD 72.03 ± 9.65 years). HbA1c dropped from 7.8 ± 1.75% to 6.8 ± 1.60% after complete remission of the symptoms of de- pression (p = 0.02). This reduction is not only statistically signifi- cant but is clinically important, considering that most antidiabetic drugs in current use are equally effective in reducing HbA1c. We are therefore convinced that caregivers need to be fully aware of the problem of depression in diabetes patients, with a view to designing a questionnaire to detect it and to plan appropriate treatment. © 2015 UTET Periodici Scientifici srl. All rights reserved. Source